Image Place holder

Pearlie K. Burnette, PharmD, PhD

Academic Rank: Senior Member


Increased awareness of the MLS burden has advanced the study of the molecular basis of this complex disease to develop new treatments.


    • Immunology
    • Malignant Hematology
    • Immunology

Education & Training


  • University of Florida, PharmD - Pharmacy
  • University of South Florida, PhD - Medical Sciences

Chronic lymphocytosis of large granular lymphocytes (LGL) associated with neutropenia and/or anemia was first described in 1985 to be the result of clonal cytogenetic abnormalities. These LGL proliferations are now recognized as being clonally derived from either CD3- or CD3+ LGL, and the resulting diseases are designated natural killer (NK)-LGL leukemia and T-LGL leukemia, respectively. Peripheral elimination of normal activated NK- and T-LGL cells occurs through apoptosis by a Fas (CD95)-mediated pathway. Therefore, the central hypothesis of Dr. Epling-Burnette and her colleagues is that the LGL cells accumulate as a result of dysregulated apoptosis and that these lymphocytes induce autoimmune destruction of myeloid and/or erythroid populations. Research in our laboratory has focused on the inhibitors of apoptosis that might directly mediate survival of these cells and contribute to their resistance to Fas signaling. We have identified several survival pathways that are chronically active in patients with these diseases and contribute to accumulation of LGL cells. Signal transducers and activators of transcription (STAT) signaling has been found to regulate antiapoptotic survival in some tumors. STATs are transcription factors initially discovered as key signaling components that moderate responses to cytokine stimulation. We have data implicating STAT3 in the survival of NK- and T-LGLs. Mcl-1 is transcriptionally regulated by STAT3 and prevents apoptosis at the level downstream of Fas receptor signaling. The mitogen-activated protein kinase (MAPK/ERK) pathway is another cascade that is important in LGL survival. We have found that MAPK/ERK was constitutively activated in 13 of 13 patients with NK-LGL leukemia and six of seven patients with T-LGL leukemia. The MAPK pathway coupled long-term survival of these LGL cells to constitutively activated Ras. These findings suggest that strategies to inhibit STAT or Ras/ERK/MAPK signaling pathways may be useful for the treatment of LGL leukemias. I am also is interested in the mechanism of bone marrow failure in patients with LGL leukemia. A large number of NK receptors (killer cell immunoglobulin-like receptors, or KIRs) are expressed on NK cells and some T cells that recognize self-HLA alleles, thereby limiting the lysis of autologous cells. Ligands of the inhibitory KIRs are classic HLA Class I molecules, and engagement of these receptors inhibits the lytic activity of NK and T cells. Activating NK receptors are important in the recognition of tumor cells and virus-infected cells and mediate target cell lysis. We have found that the repertoire of NK receptors expressed on NK-LGL cells is skewed. Interestingly, patients with NK-LGL leukemia express a large number of activating KIRs (by genotype analysis) and lower levels of inhibitory KIR mRNA and protein than normal NK cells. Consistent with a high level of activating NK receptors, the NK-LGL cells have a potent cytolytic function. These results demonstrate that patients with NK-LGL leukemia have an increased activating-to-inhibitory KIR ratio. The major hypothesis guiding this research is that this altered ratio induces inappropriate lysis or cytokine production that has an impact on bone marrow production of erythroid and/or myeloid cells.


  • Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF. A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):157-161. Pubmedid: 30713125.
  • Rollison DE, Schell MJ, Fenske NA, Cherpelis B, Messina JL, Giuliano AR, Epling-Burnette PK, Hampras S, Amorrortu RP, Balliu J, Vijayan L, Naqvi SMH, Zhao Y, Parab K, McKay-Chopin S, Gheit T, Tommasino M. Cutaneous Viral Infections Across 2 Anatomic Sites Among a Cohort of Patients Undergoing Skin Cancer Screening. J Infect Dis. 2019 Feb;219(5):711-722. Pubmedid: 30260406. Pmcid: PMC6376905.
  • Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya S, Lopez R, Pradhan K, Giricz O, Ravipati G, Wong LF, Cole S, Bhagat TD, Feld J, Dhar Y, Bartenstein M, Thiruthuvanathan VJ, Wickrema A, Ye BH, Frank DA, Pellagatti A, Boultwood J, Zhou T, Kim Y, MacLeod AR, Epling-Burnette PK, Ye M, McCoon P, Woessner R, Steidl U, Will B, Verma AK. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J Clin Invest. 2018 Sep. Pubmedid: 30252677.
  • Hampras SS, Tommasino M, Zhao Y, Messina J, Giuliano AR, Fenske N, Cherpelis B, Hesterberg R, Akuffo AA, Amorrortu RP, Balliu J, Vijayan L, Gheit T, Epling-Burnette PK, Rollison DE. Cross-sectional associations between cutaneous viral infections and regulatory T lymphocytes in circulation. Br J Dermatol. 2018 Nov. Pubmedid: 30431148.
  • Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, Zhang L, Moscinski LC, Rollison DE, Gore SD, Bejar R, Walter MJ, Sekeres MA, Komrokji RS, Epling-Burnette PK. Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood. 2018 May;131(21):2402-2405. Pubmedid: 29661788. Pmcid: PMC5969383.
  • Hesterberg RS, Cleveland JL, Epling-Burnette PK. Role of Polyamines in Immune Cell Functions. Med Sci (Basel). 2018 Mar;6(1). Pubmedid: 29517999. Pmcid: PMC5872179.
  • Zhang Q, Ball MC, Zhao Y, Balasis M, Letson C, Vedder A, List AF, Epling-Burnette PK, Komrokji RS, Padron E. Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia. Leukemia. 2018 Feb;32(2):532-538. Pubmedid: 28694526.
  • Duong VH, Padron E, Al Ali NH, Lancet JE, Hall J, Kwok B, Zhang L, Epling-Burnette PK, List AF, Komrokji RS. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes. Ann Hematol. 2018 Feb;97(2):247-254. Pubmedid: 29167940.
  • Hesterberg RS, Amorrortu RP, Zhao Y, Hampras S, Akuffo AA, Fenske N, Cherpelis B, Balliu J, Vijayan L, Epling-Burnette PK, Rollison DE. T Regulatory Cell Subpopulations Associated with Recent Ultraviolet Radiation Exposure in a Skin Cancer Screening Cohort. J Immunol. 2018 Dec;201(11):3269-3281. Pubmedid: 30389774.
  • Akuffo AA, Alontaga AY, Metcalf R, Beatty MS, Becker A, McDaniel JM, Hesterberg RS, Goodheart WE, Gunawan S, Ayaz M, Yang Y, Karim MR, Orobello ME, Daniel K, Guida W, Yoder JA, Rajadhyaksha AM, Schonbrunn E, Lawrence HR, Lawrence NJ, Epling-Burnette PK. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. J Biol Chem. 2018 Apr;293(16):6187-6200. Pubmedid: 29449372. Pmcid: PMC5912449.
  • Yue L, Bartenstein M, Zhao W, Ho WT, Han Y, Murdun C, Mailloux AW, Zhang L, Wang X, Budhathoki A, Pradhan K, Rapaport F, Wang H, Shao Z, Ren X, Steidl U, Levine RL, Zhao ZJ, Verma A, Epling-Burnette PK. Efficacy of ALK5 inhibition in myelofibrosis. JCI Insight. 2017 Apr;2(7):e90932. Pubmedid: 28405618. Pmcid: PMC5374075.
  • Hampras S, Pawlita M, Tommasino M, Park J, Burnette P, Fenske N, Cherpelis B, Rollison D. Telomere length, cutaneous beta human papillomavirus infection and cutaneous squamous cell carcinoma. Dermatol Online J. 2016 Sep;22(9). Pubmedid: 28329670.
  • Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016 May;91(5):E280-E283. Pubmedid: 26875020.
  • Dong W, Ding T, Wu L, Ren X, Epling-Burnette PK, Yang L. Effect of IL-7 and IL-15 on T cell phenotype in myelodysplastic syndromes. Oncotarget. 2016 May;7(19):27479-27488. Pubmedid: 27036031. Pmcid: PMC5053665.
  • Haider M, Al Ali N, Padron E, Epling-Burnette P, Lancet J, List A, Komrokji R. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S44-S48. Pubmedid: 27521323.
  • Dong W, Wu L, Sun H, Ren X, Epling-Burnette PK, Yang L. MDS shows a higher expression of hTERT and alternative splice variants in unactivated T-cells. Oncotarget. 2016 11;7(44):71904-71914. Pubmedid: 27655690. Pmcid: PMC5342131.
  • McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget. 2015 Oct;6(33):34437-34445. Pubmedid: 26416416. Pmcid: PMC4741464.
  • Yang L, Qian Y, Eksioglu E, Epling-Burnette PK, Wei S. The inflammatory microenvironment in MDS. Cell Mol Life Sci. 2015 May;72(10):1959-1966. Pubmedid: 25662443.
  • McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer J. 2015 Mar;5:e291. Pubmedid: 25768405. Pmcid: PMC4382654.
  • Mishra A, Rollison DE, Brandon TH, Al Ali NH, Corrales-Yepez M, Padron E, Epling-Burnette PK, Lancet JE, List AF, Komrokji RS. Impact of tobacco usage on disease outcome in myelodysplastic syndromes. Leuk Res. 2015 Jul;39(7):673-678. Pubmedid: 25934048. Pmcid: PMC5992898.
  • Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, Lancet JE, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol. 2014 Nov;133(2):249-256. Pubmedid: 25413011.
  • Padron E, Yoder S, Kunigal S, Mesa T, Teer JK, Al Ali N, Sekeres MA, Painter JS, Zhang L, Lancet J, Maciejewski JP, Epling-Burnette PK, Sotomayor E, Komrokji RS, List AF. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood. 2014 Jun;123(23):3675-3677. Pubmedid: 24904105. Pmcid: PMC4047502.
  • Komrokji RS, Mailloux AW, Chen DT, Sekeres MA, Paquette R, Fulp WJ, Sugimori C, Paleveda-Pena J, Maciejewski JP, List AF, Epling-Burnette PK. A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. Haematologica. 2014 Jul;99(7):1176-1183. Pubmedid: 24488560. Pmcid: PMC4077078.
  • Mailloux AW, Zhang L, Moscinski L, Bennett JM, Yang L, Yoder SJ, Bloom G, Wei C, Wei S, Sokol L, Loughran TP, Epling-Burnette PK. Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia. J Immunol. 2013 Oct;191(7):3578-3593. Pubmedid: 24014875. Pmcid: PMC4346227.
  • Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, Epling-Burnette P, Van Bijnen S, Dolstra H, Cannon J, Youn JI, Donatelli SS, Qin D, De Witte T, Tao J, Wang H, Cheng P, Gabrilovich DI, List A, Wei S. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest. 2013 Nov;123(11):4595-4611. Pubmedid: 24216507. Pmcid: PMC3809779.
  • Duong VH, Lancet JE, Alrawi E, Al-Ali NH, Perkins J, Field T, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leuk Res. 2013 May;37(5):510-515. Pubmedid: 23332452.
  • Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013 Jun;121(25):5068-5077. Pubmedid: 23632888. Pmcid: PMC4347259.
  • Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, Maciejewski JP, List A. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 2013 Feb;32(9):1110-1120. Pubmedid: 22525275. Pmcid: PMC3751397.
  • Mailloux AW, Epling-Burnette PK. Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes. Oncoimmunology. 2013 Feb;2(2):e22654. Pubmedid: 23524348. Pmcid: PMC3601152.
  • Anic GM, Sondak VK, Messina JL, Fenske NA, Zager JS, Cherpelis BS, Lee JH, Fulp WJ, Epling-Burnette PK, Park JY, Rollison DE. Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer Epidemiol. 2013 Aug;37(4):434-439. Pubmedid: 23523330. Pmcid: PMC3679277.
  • Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, Loughran TP, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK. Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. Leukemia. 2013 Apr;27(4):897-906. Pubmedid: 23072779. Pmcid: PMC4346223.
  • Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP, List AF, Epling-Burnette PK. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol. 2012 Sep;189(6):3198-3208. Pubmedid: 22875800. Pmcid: PMC3436939.
  • Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012 Nov;87(11):1006-1009. Pubmedid: 23090887.
  • Nyland SB, Krissinger DJ, Clemente MJ, Irby RB, Baab KT, Jarbadan NR, Sokol L, Schaefer E, Liao J, Cuthbertson D, Epling-Burnette P, Paquette R, List AF, Maciejewski JP, Loughran TP. Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. Leuk Res. 2012 May;36(5):581-587. Pubmedid: 22386729. Pmcid: PMC3312981.
  • Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012 Mar;2(3):e63. Pubmedid: 22829258. Pmcid: PMC3317526.
  • McDaniel JM, Zou JX, Fulp W, Chen DT, List AF, Epling-Burnette PK. Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation. Leukemia. 2012 Jun;26(6):1425-1429. Pubmedid: 22193963. Pmcid: PMC3321111.
  • Epling-Burnette PK, McDaniel J, Wei S, List AF. Emerging immunosuppressive drugs in myelodysplastic syndromes. Expert Opin Emerg Drugs. 2012 Dec;17(4):519-541. Pubmedid: 23163589.
  • Kriss CL, Pinilla-Ibarz JA, Mailloux AW, Powers JJ, Tang CH, Kang CW, Zanesi N, Epling-Burnette PK, Sotomayor EM, Croce CM, Del Valle JR, Hu CC. Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood. 2012 Aug;120(5):1027-1038. Pubmedid: 22692508. Pmcid: PMC3680046.
  • McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol. 2012 Aug;2012:513702. Pubmedid: 22888354. Pmcid: PMC3409527.
  • Bai F, Villagra AV, Zou J, Painter JS, Connolly K, Blaskovich MA, Sokol L, Sebti S, Djeu JY, Loughran TP, Wei S, Sotomayor E, Epling-Burnette P. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunol Immun. 2012 Apr;61(4):523-533. Pubmedid: 21983879. Pmcid: PMC4612510.
  • Zhou J, Wu J, Chen X, Fortenbery N, Eksioglu E, Kodumudi KN, Epling-Burnette PK, Dong J, Djeu JY, Wei S. Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions. Int Immunopharmacol. 2011 Jul;11(7):890-898. Pubmedid: 21244860. Pmcid: PMC3109231.
  • Zhou J, Eksioglu EA, Fortenbery NR, Chen X, Wang H, Epling-Burnette PK, Djeu JY, Wei S. Bone marrow mononuclear cells up-regulate toll-like receptor expression and produce inflammatory mediators in response to cigarette smoke extract. PLoS One. 2011 Dec;6(6):e21173. Pubmedid: 21738617. Pmcid: PMC3126797.
  • Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, Meléndez-Santiago J, Fulp W, Komrokji R, Lancet J, List AF. Telomere length in myelodysplastic syndromes. Leuk Lymphoma. 2011 Aug;52(8):1528-1536. Pubmedid: 21635204. Pmcid: PMC4350661.
  • Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, Sotomayor EM, Pinilla-Ibarz JA. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma. 2011 Apr;52(4):668-679. Pubmedid: 21271862. Pmcid: PMC4487410.
  • Epling-Burnette PK, List AF. Advancements in the molecular pathogenesis of myelodysplastic syndrome. Curr Opin Hematol. 2009 Mar;16(2):70-76. Pubmedid: 19468267.
  • Zou JX, Rollison DE, Boulware D, Chen DT, Sloand EM, Pfannes LV, Goronzy JJ, Bai F, Painter JS, Wei S, Cosgrove D, List AF, Epling-Burnette PK. Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia. 2009 Jul;23(7):1288-1296. Pubmedid: 19282834. Pmcid: PMC3252820.
  • Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A. 2009 Aug;106(31):12974-12979. Pubmedid: 19470455. Pmcid: PMC2722346.
  • Chen X, Bai F, Sokol L, Zhou J, Ren A, Painter JS, Liu J, Sallman DA, Chen YA, Yoder JA, Djeu JY, Loughran TP, Epling-Burnette PK, Wei S. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood. 2009 Apr;113(14):3226-3234. Pubmedid: 19075187. Pmcid: PMC2665892.
  • Lai D, Loughran TP J, Maciejewski J, Sasu S, Song S, Burnette P, Paquette R. Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia associated with an occult large granular lymphocyte leukemia. Leuk Res. 2008 May;32(5):823-827. Pubmedid: 17915315.
  • Bourgault-Rouxel A, Loughran TP, Zambello R, Burnette P, SemenzatoG, Donadieu J, Amiot L, Fest T, Lamy T. Clinical spectrum of gammadelta+ T cell LGL leukemia: analysis of 20 cases. Leuk Res. 2008 Jan;32(1):45-48. Pubmedid: 17544120.
  • Jiang K, Apostolatos AH, Ghansah T, Watson JE, Vickers T, Cooper DR, Epling-Burnette PK, Patel NA. Identification of a novel antiapoptotic human protein kinase C delta isoform, PKCdeltaVIII in NT2 cells. Biochemistry-Us. 2008 Jan;47(2):787-797. Pubmedid: 18092819.
  • Yang J, Epling-Burnette PK, Painter JS, Zou J, Bai F, Wei S, Loughran TP. Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood. 2008 Feb;111(3):1610-1616. Pubmedid: 17993614. Pmcid: PMC2214759.
  • Epling-Burnette PK, Sokol L, Chen X, Bai F, Zhou J, Blaskovich MA, Zou J, Painter JS, Edwards TD, Moscinski L, Yoder JA, Djeu JY, Sebti S, Loughran TP, Wei S. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood. 2008 Dec;112(12):4694-4698. Pubmedid: 18791165. Pmcid: PMC2597136.
  • Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, ZouJ, Ku E, Zhong B, Boulware D, Moscinski L, Wei S, Djeu JY, List AF. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007 Jun;109(11):4816-4824. Pubmedid: 17341666. Pmcid: PMC1885518.
  • Epling-Burnette PK, Painter JS, Rollison DE, Ku E, Vendron D, Widen R, Boulware D, Zou JX, Bai F, List AF. Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia. 2007 Apr;21(4):659-667. Pubmedid: 17301813.
  • Gallagher S, Peng Y, Haines K, Baksh K, Epling-Burnette P, Yang J, Murr MM. Fas/FasL play a central role in pancreatitis-induced hepatocyte apoptosis. J Gastrointest Surg. 2005 Apr;9(4):467-474. Pubmedid: 15797225.
  • Epling-Burnette P, Painter J, Bai F, Wei S, Djeu J, LoughranTP. Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood. 2004 May;103(9):3431-3439. Pubmedid: 14726391.
  • Epling-Burnette PK, Bai F, Wei S, Painter JS, Olashaw N, Hamilton A, Sebti S, Djeu JY, Loughran TP. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene. 2004 Dec;23(57):9220-9229. Pubmedid: 15516985.
  • Yang J, Gallagher S, Haines K, Epling-Burnette P, Bai F, Gower WR J, Mastorides S, Norman J, Murr M. Kupffer cell-derived Fas ligand plays a role in liver injury and hepatocyte death. J Gastrointest Surg. 2004;8(2):166-174. Pubmedid: 15036192.
  • Gallagher S, Yang J, Baksh K, Haines K, Carpenter H, Epling-Burnette P, Peng Y, Norman J, Murr M. Acute pancreatitis induces FasL gene expression and apoptosis in the liver. J Surg Res. 2004;122(2):201-209. Pubmedid: 15555619.
  • Mohapatra S, Chu B, Wei S, Djeu J, Epling-Burnette PK, Loughran T, Jove R, Pledger WJ. Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res. 2003 Dec;63(23):8523-8530. Pubmedid: 14679020.
  • Zhong B, Jiang K, Gilvary DL, Epling-Burnette PK, Ritchey C, Liu J, Jackson RJ, Hong-Geller E, Wei S. Human neutrophils utilize a Rac/Cdc42-dependent MAPK pathway to direct intracellular granule mobilization toward ingested microbial pathogens. Blood. 2003 Apr;101(8):3240-3248. Pubmedid: 12511425.
  • Kothapalli R, Bailey R, Kusmartseva I, Mane S, Epling-Burnette P, Loughran TP. Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia. Int J Oncol. 2003;22(1):33-39. Pubmedid: 12469182.
  • Epling-Burnette P, Loughran TP J. Survival signals in leukemic large granular lymphocytes. Semin Hematol. 2003;40:213-220. Pubmedid: 12876670.
  • Yang J, Fier A, Carter Y, Liu G, Epling-Burnette P, Bai F, Loughran TP J, Mastorides S, Norman J, Murr M. Liver injury during acute pancreatitis: the role of pancreatitis-associated ascitic fluid (PAAF), p38-MAPK, and caspase-3 in inducing hepatocyte apoptosis. J Gastrointest Surg. 2003;7(2):200-208. Pubmedid: 12600444.
  • Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2002 Oct;62(20):5761-5769. Pubmedid: 12384536.
  • Epling-Burnette PK, Garcia R, Bai F, Ismail S, Loughran TP, Djeu J, Jove R, Wei S. Carboxy-terminal truncated STAT5 is induced by interleukin-2 and GM-CSF in human neutrophils. Cell Immunol. 2002 May;217(1-2):1-11. Pubmedid: 12425996.
  • Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 2002 Dec;21(57):8804-8816. Pubmedid: 12483533.
  • Liu J, Wei S, Lamy T, Yongxiang L, Epling-Burnette P, Djeu J, Loughran T. Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood. 2002 Aug;100(4):1449-1453. Pubmedid: 12149230.
  • Murr M, Yang J, Fier A, Foulis P, Loughran T, Epling-Burnette P, Norman J. Pancreatitis-associated ascitic fluid induces hepatocyte death independent of local cytokines. J Surg Res. 2002;106(2):308-313. Pubmedid: 12175984.
  • Epling-Burnette PK, Zhong B, Bai F, Jiang K, Bailey RD, Garcia R, Jove R, Djeu JY, Loughran TP, Wei S. Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J Immunol. 2001 Jun;166(12):7486-7495. Pubmedid: 11390502.
  • Epling-Burnette P, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R, Loughran TP. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001 Feb;107(3):351-362. Pubmedid: 11160159. Pmcid: PMC199188.
  • Wei S, Liu JH, Epling-Burnette PK, Jiang K, Zhong B, Elkabani ME, Pearson EW, Djeu JY. IL-2 induces the association of IL-2Rbeta, lyn, and MAP kinase ERK-1 in human neutrophils. Immunobiology. 2000 Nov;202(4):363-382. Pubmedid: 11131153.
  • Liu J, Wei S, Lamy T, Loughran, Jr. T, Epling-Burnette P, Starkebaum G, Djeu J. Chronic neutropenia mediated by fas ligand. Blood. 2000 May;95(10):3219-3222. Pubmedid: 10807792.
  • Liu J, Wei S, Burnette P, Gamero A, Hutton M, Djeu J. Functional association of TGF-beta receptor II with cyclin B. Oncogene. 1999 Jan;18(1):269-275. Pubmedid: 9926943.
  • Pericle F, Burnette P, Podack E, Wei S, Djeu J. CD40-CD40L interactions provide "third-party" costimulation for T cell response against B7-1-transfected human breast tumor cells. J Leukoc Biol. 1997 Feb;61(2):201-208. Pubmedid: 9021926.
  • Spranzi E, Djeu JY, Hoffman SL, Epling-Burnette PK, Blanchard DK. Lysis of human monocytic leukemia cells by extracellular adenosine triphosphate: mechanism and characterization of the adenosine triphosphate receptor. Blood. 1993 Sep;82(5):1578-1585. Pubmedid: 8364207.
  • Epling-Burnette PK, Wei S, Blanchard DK, Spranzi E, Djeu JY. Coinduction of granulocyte-macrophage colony-stimulating factor release and lymphokine-activated killer cell susceptibility in monocytes by interleukin-2 via interleukin-2 receptor beta. Blood. 1993 Jun;81(11):3130-3137. Pubmedid: 8499646.
  • Burnette P, Wei S, Blanchard D, Spranzi E, Djeu J. Co-induction of GM-CSF release and LAK susceptibility in monocytes by IL-2 via Il-2R(beta). Blood. 1993;81:3130-3130.
  • Burnette PK, Perkins J. Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting. Pharmacotherapy. 1992;12(2):120-131. Pubmedid: 1533280.
  • Mattingly PM, Burnette PK, Weston MW, Manny RP. Pancytopenia secondary to short-term, high-dose intravenous infusion of amrinone. DICP. 1990 Dec;24(12):1172-1174. Pubmedid: 2089824.
  • Burnette PK, Ameer B, Hoang V, Phifer W. Rifampin-associated thrombocytopenia secondary to poor compliance. DICP. 1989 May;23(5):382-384. Pubmedid: 2728526.